Advertisement
Canada markets close in 12 minutes

  • S&P/TSX

    21,783.56
    +75.12 (+0.35%)
     

  • S&P 500

    4,962.52
    -48.60 (-0.97%)
     

  • DOW

    37,970.84
    +195.46 (+0.52%)
     

  • CAD/USD

    0.7272
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    83.22
    +0.49 (+0.59%)
     

  • Bitcoin CAD

    88,206.40
    +1,087.12 (+1.25%)
     

  • CMC Crypto 200

    1,384.14
    +71.52 (+5.45%)
     

  • GOLD FUTURES

    2,407.60
    +9.60 (+0.40%)
     

  • RUSSELL 2000

    1,940.24
    -2.72 (-0.14%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,249.18
    -352.32 (-2.26%)
     

  • VOLATILITY

    18.88
    +0.88 (+4.89%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

Carrick Therapeutics
·2 min read

Collaboration leverages Roche’s MORPHEUS platform to accelerate development of samuraciclib in combination with Roche’s giredestrant

DUBLIN, Ireland and BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The collaboration will utilize Roche’s MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.

This new study expands Carrick’s portfolio of clinical trials with samuraciclib, which is also being evaluated in a Phase 2a study in combination with fulvestrant for CDK4/6i resistant HR+, HER2- metastatic breast cancer. Other ongoing studies include samuraciclib for the treatment of triple negative breast cancer (TNBC) and prostate cancer – all settings in which CDK7 has been shown to act as a regulator of transcription, the cell cycle and endocrine receptor signalling.

“We are excited to initiate this collaboration with Roche to explore the broad potential of samuraciclib in combination with giredestrant, a next-generation oral SERD,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “Carrick’s preclinical studies have shown strong synergy combining CDK7 inhibitors with endocrine therapies, including models of resistance to CDK4/6 inhibitors. This collaboration represents a shared commitment to maximize the potential of innovative combination treatment approaches and address significant unmet needs.”

ADVERTISEMENT

Under the agreement, each company is supplying its respective anti-cancer agent to support the trial.

About Samuraciclib (CT7001)

Samuraciclib is the most advanced oral CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy. Samuraciclib has demonstrated a favourable safety profile and encouraging efficacy in early clinical studies.

About Roche MORPHEUS Platform

The MORPHEUS platform consists of multiple, global, open-label, randomized, umbrella Phase 1b/2 trials designed to accelerate the development of combinations for several indications by identifying early signals and establishing proof-of-concept clinical data.

About Carrick Therapeutics

Carrick Therapeutics is an oncology-focused biopharmaceutical company leveraging its deep expertise to discover highly differentiated novel therapies that address significant unmet needs. Samuraciclib, the most advanced oral CDK7 inhibitor in clinical development, is currently being evaluated in Phase 2a studies targeting CDK4/6 inhibitor resistant second-line HR+, HER2- metastatic breast cancer. Samuraciclib is also being evaluated in triple negative breast cancer (TNBC) and prostate cancer with further potential in pancreatic, ovarian and colorectal cancers. Carrick is also developing a novel CDK12/13 inhibitor / Cyclin-K glue-degrader which has advanced into IND enabling toxicology studies.

For more information about Carrick Therapeutics, please visit www.carricktherapeutics.com

Contact

Carrick Therapeutics
Jenny Horsfield, Senior Vice President Business Development
jenny.horsfield@carricktherapeutics.com

Investors and Media
William Slattery, Jr., Real Chemistry
wslattery@realchemistry.com